Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital

NCT: NCT07531667 · COMPLETED

NCT IDNCT07531667
StatusCOMPLETED
Start Date2022-05-01
Completion2022-08-01

Brief Summary

Background: Homonymous hemianopia is a visual field defect that causes functional disabilities, such as decreased self-confidence, limited mobility, and increased risk of falls. Studies related to the effectiveness and comfort of Fresnel prisms, especially in the Indonesian population are limited. Objective: To evaluate the effectiveness and comfort level of Fresnel prisms in expanding visual field in an Indonesian patient population with homonymous hemianopia.

Frequently Asked Questions

What is Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital?

Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital is a clinical trial registered under NCT07531667. Current status: COMPLETED.

What is the status of NCT07531667?

The current status of NCT07531667 (Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital) is: COMPLETED.

When did Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital start?

Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital started on 2022-05-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.